Enovis Corporation (NYSE:ENOV) released its quarterly earnings results on Thursday, revealing a strong performance that exceeded analysts’ expectations. The company reported earnings of $0.75 per share, surpassing the consensus estimate of $0.67 by $0.08. Additionally, Enovis generated revenue of $548.91 million for the quarter, which was above analysts’ forecast of $538.61 million. This represents an 8.7% increase in revenue compared to the same period last year, when the company posted earnings of $0.73 per share.
The report also highlighted a negative net margin of 37.80% and a return on equity of 6.78%. Following the earnings announcement, Enovis updated its full-year guidance for 2025, projecting earnings per share to range between $3.100 and $3.250.
Stock Performance and Market Reactions
Despite the positive earnings news, Enovis shares experienced a 1.4% decline in mid-day trading on Friday, falling by $0.41 to $28.02. During this trading session, a total of 1,092,886 shares exchanged hands, slightly below the average volume of 1,104,868. The company’s market capitalization stands at $1.60 billion, with a price-to-earnings ratio of -1.97 and a beta of 1.67. Over the past year, the stock has fluctuated, reaching a low of $25.47 and a high of $49.75.
Analysts have reacted to the earnings report with mixed sentiments. Canaccord Genuity Group recently reduced its price target for Enovis from $70.00 to $58.00, maintaining a “buy” rating. Similarly, UBS Group lowered its target from $65.00 to $57.00, while Needham & Company set a new target of $49.00. Currently, six analysts rate the stock as a “buy,” while one analyst has issued a “sell” rating, leading to an average rating of “Moderate Buy” with a target price of $51.17 according to MarketBeat.com.
Insider Activity and Institutional Investments
In related news, insider trading activity has been notable. Senior Vice President Bradley J. Tandy purchased 3,200 shares at an average price of $31.41 per share on August 22nd, totaling $100,512.00. Following this acquisition, Tandy holds 43,515 shares, valued at approximately $1.37 million. Additionally, Chief Financial Officer Phillip Benjamin (Ben) Berry bought 2,500 shares for $29.71 each, increasing his holdings to 116,729 shares, worth about $3.47 million.
Over the past 90 days, insiders have acquired a total of 12,157 shares, valued at $374,760, indicating a growing confidence among management. Currently, corporate insiders own 2.70% of the company’s stock.
Institutional investors have also shown significant interest in Enovis. AQR Capital Management LLC increased its holdings by 682.6% in the second quarter, now owning 498,317 shares worth $15.63 million. Other notable institutional players include Paradigm Capital Management Inc. NY, which raised its stake by 41.6%, and P2 Capital Partners LLC, which boosted its investment by 87.0%. Collectively, institutional investors hold 98.45% of Enovis’ stock.
Enovis Corporation specializes in medical technology, focusing on creating clinically differentiated solutions globally. The company manufactures and distributes medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. It operates through two primary segments: Prevention and Recovery and Reconstructive.
